Cullinan Oncology
CGEM
71 hedge funds and large institutions have $795M invested in Cullinan Oncology in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 17 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
1% more funds holding
Funds holding: 70 → 71 (+1)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
1.55% less ownership
Funds ownership: 75.66% → 74.11% (-1.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
39% less capital invested
Capital invested by funds: $1.3B → $795M (-$504M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIG
American International Group
New York
|
+$37.6M |
| 2 |
DM
Deerfield Management
New York
|
+$32.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.3M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$9.06M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$8.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$30.2M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$29.5M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$10.4M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$9.66M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.11M |
CGEM Hedge Fund Activity: Q2 2021 in Review
71 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q2 2021, worth a combined $795M — down 39% from $1.3B a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CGEM positions and 17 closed out — a net gain of 1 holder — while 22 added to existing stakes and 19 trimmed.
The largest buyer was American International Group, adding an estimated $37.6M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $30.2M sold.
- 71 institutional investors held Cullinan Oncology (CGEM) as of Q2 2021, up from 70 in Q1 2021.
- Funds reported $795M of Cullinan Oncology stock for Q2 2021, down 39% quarter-over-quarter.
- 18 funds opened new Cullinan Oncology positions in Q2 2021 and 17 closed out, a net change of +1 holder.
- The largest Cullinan Oncology buyer in Q2 2021 was American International Group, an estimated $37.6M added.
- The largest Cullinan Oncology seller in Q2 2021 was T. Rowe Price Associates, an estimated $30.2M sold.
Based on aggregated 13F filings for Q2 2021.